Skip to Content

Cyltezo FDA Approval History

FDA Approved: Yes (First approved August 25, 2017)
Brand name: Cyltezo
Generic name: adalimumab-adbm
Dosage form: Injection
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Acute, Crohn's Disease, Maintenance, Ulcerative Colitis, Plaque Psoriasis

Cyltezo (adalimumab-adbm) is an anti-TNF-α monoclonal antibody biosimilar to Humira, approved for the treatment of various inflammatory diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.

Development Timeline for Cyltezo

DateArticle
Aug 29, 2017Approval FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.